LOR-2501

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLOR-2501
Drug Alias NameGTI-2501LOR-2501
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionRibonucleoside-diphosphate reductase M1 chain inhibitors
TargetsRibonucleoside-diphosphate reductase M1 chain
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAptose
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAptose
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A